Corticosterone

Summary

Corticosterone (CHEMBL110739) is a phase-3 clinical-stage small molecule targeting NR3C1 and NR3C2; indicated across 1 condition including osteoarthritis, hip.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 2 (NR3C1, NR3C2)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 346.5 Da · C21H30O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL110739
Name	Corticosterone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5753
ChEBI	CHEBI:16827
Molecular formula	C21H30O4
Molecular weight	346.5
InChIKey	OMFXVFTZEKFJBZ-HJTSIMOOSA-N

SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C)O

IUPAC name: (8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

ChEBI definition: A 21-hydroxy steroid that consists of pregn-4-ene substituted by hydroxy groups at positions 11 and 21 and oxo groups at positions 3 and 20. Corticosterone is a 21-carbon steroid hormone of the corticosteroid type produced in the cortex of the adrenal glands.

Other ChEBI roles (chemical / environmental): human metabolite, mouse metabolite.

Also known as: Corticosterone, Kendall’s compound b, NSC-9705, Reichstein’s substance h, corticosterone, corticostereone, SID17389502, SID855741, SID90341091, SID56423132, SID26751495, SID144204430

Patent coverage: 8,441 distinct patent families (28,274 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR3C1	Glucocorticoid receptor	Agonist	7.2	0.9%	P04150
NR3C2	Mineralocorticoid receptor	Agonist		0%	P08235

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Survival motor neuron protein, Thrombopoietin, Solute carrier family 22 member 2, Solute carrier family 22 member 2, Solute carrier family 22 member 3, Solute carrier organic anion transporter family member 1A1, Mineralocorticoid receptor, Solute carrier family 22 member 1, Solute carrier family 22 member 3, Corticosteroid-binding globulin.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 33 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C2	9.3	Kd	0.5	nM	CHEMBL_ACT_18033281
SERPINA6	7.88	Ki	13.18	nM	CHEMBL_ACT_950012
NFKB1	7.7	Potency	20	nM	CHEMBL_ACT_3675702
NFKB1	7.7	Potency	20	nM	CHEMBL_ACT_4588884
HIF1A	7.2	Potency	63.1	nM	CHEMBL_ACT_4128768
HIF1A	7.2	Potency	63.1	nM	CHEMBL_ACT_4518561
SERPINA6	7.2	Ki	63.1	nM	CHEMBL_ACT_955302
SLC22A3	6.54	IC50	290	nM	CHEMBL_ACT_11000855
Q9R0W2	6.41	Ki	390	nM	CHEMBL_ACT_11002280
Q9R0W2	6.38	Ki	420	nM	CHEMBL_ACT_11002283
Q9R0W2	6.34	Ki	460	nM	CHEMBL_ACT_11002288
SHBG	6.34	Kd	457.1	nM	CHEMBL_ACT_2155684
Q9R0W2	6.22	Ki	605	nM	CHEMBL_ACT_11002299
SMN1	6.05	Potency	891.3	nM	CHEMBL_ACT_3875073
THPO	5.9	Potency	1259	nM	CHEMBL_ACT_4805508
THPO	5.9	Potency	1259	nM	CHEMBL_ACT_5070259
SLC22A3	5.8	IC50	1600	nM	CHEMBL_ACT_24930910
MAPK1	5.5	Potency	3162	nM	CHEMBL_ACT_4524576
Q9R0W2	5.4	IC50	4000	nM	CHEMBL_ACT_11001760
Q9R0W2	5.38	IC50	4200	nM	CHEMBL_ACT_11001468
O88446	5.31	IC50	4900	nM	CHEMBL_ACT_11001726
P46720	5.28	Ki	5300	nM	CHEMBL_ACT_11003170
SLC22A1	5.15	Ki	7020	nM	CHEMBL_ACT_11003243
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_4973400
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_5038625

Target pathways

Aggregated over 2 target gene(s): NR3C1, NR3C2.

Top Reactome pathways

14 total, by targets touching each:

Pathway	Targets	Genes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	2	NR3C1, NR3C2
Nuclear Receptor transcription pathway	2	NR3C1, NR3C2
SUMOylation of intracellular receptors	2	NR3C1, NR3C2
Cellular responses to stress	1	NR3C2
SUMOylation	1	NR3C2
SUMO E3 ligases SUMOylate target proteins	1	NR3C2
Metabolism of proteins	1	NR3C2
Post-translational protein modification	1	NR3C2
PTK6 Expression	1	NR3C1
Regulation of RUNX2 expression and activity	1	NR3C1
Cellular responses to stimuli	1	NR3C2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	1	NR3C1
Potential therapeutics for SARS	1	NR3C1
Regulation of NPAS4 gene transcription	1	NR3C1

Dominant GO biological processes

GO term	Targets
regulation of DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
signal transduction	2
nuclear receptor-mediated steroid hormone signaling pathway	2
negative regulation of transcription by RNA polymerase II	1
regulation of gluconeogenesis	1
chromatin organization	1
apoptotic process	1
chromosome segregation	1
glucocorticoid metabolic process	1
response to wounding	1
gene expression	1
microglia differentiation	1
adrenal gland development	1
regulation of glucocorticoid biosynthetic process	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, hip	3	MONDO:0006629	EFO:1000786

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01079455	PHASE3	UNKNOWN	Comparison of Hyaluronic Acid and Corticosteroid Intra-articular Injections for the Treatment of Osteoarthritis of the Hip

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

179 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ENZALUTAMIDE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2
EPLERENONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2
FLUDROCORTISONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C1, NR3C2
BUDESONIDE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
HYDROCORTISONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
HYDROCORTISONE BUTYRATE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
PREDNISOLONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
PROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	NR3C1, NR3C2
ASOPRISNIL	ChEMBL	Phase 3	NR3C1, NR3C2
BALCINRENONE	ChEMBL	Phase 3	NR3C1, NR3C2
METRIBOLONE	ChEMBL	Phase 2	NR3C1, NR3C2
ONAPRISTONE	ChEMBL	Phase 2	NR3C1, NR3C2
STANOLONE	ChEMBL	Phase 2	NR3C1, NR3C2
TUROFEXORATE ISOPROPYL	ChEMBL	Phase 2	NR3C1, NR3C2
FULVESTRANT	ChEMBL + PubChem	Phase 4 (approved)	NR3C1
PODOFILOX	ChEMBL + PubChem	Phase 4 (approved)	NR3C1
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	NR3C1
ACENOCOUMAROL	ChEMBL	Phase 4 (approved)	NR3C1
ALCLOMETASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
AMCINONIDE	ChEMBL	Phase 4 (approved)	NR3C1
AMIODARONE	ChEMBL	Phase 4 (approved)	NR3C1
APREPITANT	ChEMBL	Phase 4 (approved)	NR3C1
AURANOFIN	ChEMBL	Phase 4 (approved)	NR3C1
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	NR3C1
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
BENZBROMARONE	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE PHOSPHORIC ACID	ChEMBL	Phase 4 (approved)	NR3C1
BETAMETHASONE VALERATE	ChEMBL	Phase 4 (approved)	NR3C1
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	NR3C1
CANRENONE	ChEMBL	Phase 4 (approved)	NR3C1
CHLORMADINONE	ChEMBL	Phase 4 (approved)	NR3C1
CICLESONIDE	ChEMBL	Phase 4 (approved)	NR3C1
CLOBETASOL PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C1
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	NR3C1
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	NR3C1
CORTISONE	ChEMBL	Phase 4 (approved)	NR3C1
DANAZOL	ChEMBL	Phase 4 (approved)	NR3C1
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1
DEFLAZACORT	ChEMBL	Phase 4 (approved)	NR3C1
DESOGESTREL	ChEMBL	Phase 4 (approved)	NR3C1
DESONIDE	ChEMBL	Phase 4 (approved)	NR3C1
DESOXIMETASONE	ChEMBL	Phase 4 (approved)	NR3C1
DESOXYCORTICOSTERONE PIVALATE	ChEMBL	Phase 4 (approved)	NR3C1
DEXTROTHYROXINE	ChEMBL	Phase 4 (approved)	NR3C1
DIENESTROL	ChEMBL	Phase 4 (approved)	NR3C1
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	NR3C1
DIFLORASONE DIACETATE	ChEMBL	Phase 4 (approved)	NR3C1
DOXORUBICIN	ChEMBL	Phase 4 (approved)	NR3C1
DROSPIRENONE	ChEMBL	Phase 4 (approved)	NR3C1
ECONAZOLE	ChEMBL	Phase 4 (approved)	NR3C1
EFAVIRENZ	ChEMBL	Phase 4 (approved)	NR3C1